DAY 4 – Late-Breaking Abstract Session
We close out the 2019 ASH meeting with one final presentation from the late-breaking abstract session. The myeloma community is proud to have a myeloma study highlighted amongst all other practice-changing results presented during this session!
Dr. Saad Usmani from Levine Cancer Institute in Charlotte, North Carolina had the honor in presenting his results from a phase 3 trial called CANDOR that compared the use of Darzalex combined with Kyprolis-dexamethasone (DaraKd) to Kyprolis-dexamethasone (Kd) for patients with relapsed/refractory myeloma (ABSTRACT LBA-6 https://ash.confex.com/ash/2019/webprogram/Paper132629.html).
- Over 460 patients were randomized to receive either DaraKd (312 patients) or Kd (154 patients).
- Time until disease progression was 16 months for patients treated with Kd and could not yet be determined for patients treated with DaraKd—representing a 37% reduction in the risk of progression or death with DaraKd.
- More patients responded to DaraKd (84%) than to Kd (75%) and more patients achieved a complete response and MRD negativity with DaraKd treatment than with Kd.
- All side effects were manageable and treatment discontinuation due to side effects was similar in both treatment groups.
Compared to Kd alone, treatment with DaraKd resulted in:
- Deeper responses, with a nearly 10-times higher MRD negative/complete response rate
- A durable PFS benefit across subgroups of patients like those who had previously been treated with Revlimid and who were refectory to Revlimid
These results mark the latest combination strategy that incorporates Darzalex for treatment of patients with relapsed/refractory myeloma.